I do not think a single modafinil study settles anything, but the aggregate is more interesting than any individual paper.
My rule now: if a claim cannot survive being written down with the numbers attached, it is marketing.
If you need three other compounds to notice the first one, you have not tested the first one.
What would change your mind about this?
Baseline first. Eight months in on modafinil and it lines up.
Cold storage, light protection, date on the vial. Boring, removes half the variables.
An inconclusive account is useful if it stops the next person mistaking a story for a controlled comparison. Eight months in on modafinil and it lines up.
Most of what is called evidence here is one person, one vial, one month.
Sleep, food, or the compound? Yes. Not on modafinil but the pattern is familiar.
Name the active ingredient, not just the brand. It makes these threads searchable years later.
This board overrates bloodwork. A number moving is not the outcome you wanted.
Stupid question: how do you know whether what is in the vial matches the label at all?
Narrow conclusion. Currently on modafinil myself.
Read the methods section. It is the only part that says whether the conclusion is allowed to exist.
Is a baseline blood test really necessary before starting something like this?
I would take the narrow conclusion. Broad ones are more interesting and less true.
Narrow conclusion, briefly right. Broad conclusion, interestingly wrong. I know which I keep choosing.
An inconclusive account is useful if it stops the next person mistaking a story for a controlled comparison. Not on modafinil but the pattern is familiar.